November 25, 2024

J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis – PMLiVE

November 25, 2024

Johnson & Johnson Reports Promising Results for Psoriasis Treatment Study – MyChesCo

November 22, 2024

Icotrokinra: New treatment for moderate to severe plaque psoriasis – Open Access Government

November 22, 2024

Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis – Dermatology Times

November 21, 2024

Oral IL-23 inhibitor icotrokinra shows efficacy for plaque psoriasis – Healio